

FOR IMMEDIATE RELEASE**Apogee Investor Contact:**

Kelly Black

Premier Funding & Financial Marketing

480-649-8224

kblack@premierfundingservice.com

Apogee files Two U.S. Patent Applications Supporting its Intradermal Drug Delivery System

NORWOOD, Mass. (July 19, 2007) — Apogee Technology, Inc. (AMEX: ATA), a biotechnology company that develops drug delivery and sensor systems, announced today that it has filed two U.S. provisional patent applications relating to its intradermal drug delivery technology. The new patent applications describe advanced macromolecular formulations and coating methodologies.

Dr. Alexander K. Andrianov, Apogee's Vice President of Research and Development said, "These filings are an important achievement of the company's ongoing research and development program and are intended to protect rights for formulations with improved coating efficiency, methods and systems for precise dose control. If issued, these patent applications will constitute an important contribution to our intellectual property position."

About Apogee Technology, Inc.

Apogee Technology designs, develops and commercializes proprietary drug delivery and sensor products using its MEMS and nanotechnology for its application markets. The Company is developing its PyraDerm™ solution for enhanced intradermal drug delivery and has introduced a family of pressure sensors under the Sensilica® brand. Apogee's goal is to provide value-added and cost-saving solutions for our customers and, in so doing, become a global leader in the drug delivery and sensor fields. For more information please visit our web site at: <http://www.apogeebio.com>.

##

PyraDerm™ and Sensilica® are trademarks of Apogee Technology, Inc. All other product names noted herein may be trademarks of their respective holders. Certain statements made herein that use the words "anticipate," "may," "hope," "estimate," "project," "will," "intend," "plan," "expect," "believe" and similar expressions are intended to identify forward-looking statements within the meaning of the

Private Securities Litigation Reform Act of 1995. These forward-looking statements involve the design, development and production efforts of our PyraDerm™ and Sensilica® technologies, known and unknown risks and uncertainties, which could cause the actual results, performance or achievements of the Company to be materially different from those that may be expressed or implied. Please refer to the company's risk factors as set forth in the Company's filings with the Securities and Exchange Commission, including its reports on Forms 10-KSB, as amended, for the year ended December 31, 2006 and 10-QSB for the quarter ended March 31, 2007.